npj Parkinson's Disease (Oct 2024)

Parkinson’s families project: a UK-wide study of early onset and familial Parkinson’s disease

  • Clodagh Towns,
  • Zih-Hua Fang,
  • Manuela M. X. Tan,
  • Simona Jasaityte,
  • Theresa M. Schmaderer,
  • Eleanor J. Stafford,
  • Miriam Pollard,
  • Russel Tilney,
  • Megan Hodgson,
  • Lesley Wu,
  • Robyn Labrum,
  • Jason Hehir,
  • James Polke,
  • Lara M. Lange,
  • Anthony H. V. Schapira,
  • Kailash P. Bhatia,
  • Parkinson’s Families Project (PFP) Study Group,
  • Global Parkinson’s Genetics Program (GP2),
  • Andrew B. Singleton,
  • Cornelis Blauwendraat,
  • Christine Klein,
  • Henry Houlden,
  • Nicholas W. Wood,
  • Paul R. Jarman,
  • Huw R. Morris,
  • Raquel Real

DOI
https://doi.org/10.1038/s41531-024-00778-z
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 13

Abstract

Read online

Abstract The Parkinson’s Families Project is a UK-wide study aimed at identifying genetic variation associated with familial and early-onset Parkinson’s disease (PD). We recruited individuals with a clinical diagnosis of PD and age at motor symptom onset ≤45 years and/or a family history of PD in up to third-degree relatives. Where possible, we also recruited affected and unaffected relatives. We analysed DNA samples with a combination of single nucleotide polymorphism (SNP) array genotyping, multiplex ligation-dependent probe amplification (MLPA), and whole-genome sequencing (WGS). We investigated the association between identified pathogenic mutations and demographic and clinical factors such as age at motor symptom onset, family history, motor symptoms (MDS-UPDRS) and cognitive performance (MoCA). We performed baseline genetic analysis in 718 families, of which 205 had sporadic early-onset PD (sEOPD), 113 had familial early-onset PD (fEOPD), and 400 had late-onset familial PD (fLOPD). 69 (9.6%) of these families carried pathogenic variants in known monogenic PD-related genes. The rate of a molecular diagnosis increased to 28.1% in PD with motor onset ≤35 years. We identified pathogenic variants in LRRK2 in 4.2% of families, and biallelic pathogenic variants in PRKN in 3.6% of families. We also identified two families with SNCA duplications and three families with a pathogenic repeat expansion in ATXN2, as well as single families with pathogenic variants in VCP, PINK1, PNPLA6, PLA2G6, SPG7, GCH1, and RAB32. An additional 73 (10.2%) families were carriers of at least one pathogenic or risk GBA1 variant. Most early-onset and familial PD cases do not have a known genetic cause, indicating that there are likely to be further monogenic causes for PD.